Artiva Biotherapeutics, Inc. (ARTV): Fair Value Consensus

Symbol and logo of brand Artiva (ARTV)

Artiva Biotherapeutics, Inc. (ARTV) focuses on developing NK-therapies to combat tumors and autoimmunity, leveraging a network of clinics and strategic alliances. A team of top-tier geneticists is developing innovative drugs backed by a robust R&D budget. The company's price chart on GURU.Markets is currently at 20.85. However, a full bet on early-stage research creates significant risks dependent on the outcomes of laboratory trials.

ARTV - Artiva Biotherapeutics Consensus Target over the range 07/20/2024 - 11/17/2026

Analytical breakdowns for artivabio.com (ARTV)

- stock value and consensus price forecast:
Fundamental company analysis:Artiva (ARTV)
Original product of Artiva Biotherapeutics, Inc.

This indicator represents the arithmetic mean of Wall Street analysts' target prices, reflecting the aggregate market assessment of the asset's fair value. By analyzing the consensus projected value of the security, an investor can gauge market expectations regarding the capitalization of Artiva Biotherapeutics, Inc. (ARTV), which depends directly on the success of its scientific collaborations in developing innovative cell-based cancer therapies.

Competing companies

ONC - Average Forecast Price|Analyst Consensus Forecast HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines Corp - Price Target Chart|AAPG - Price Target Chart|Average Forecast Price cgoncology.com|UroGen (URGN) - Price Target Chart|Broker Consensus Forecast BCAX|PSNL (Personalis Genomics) - Analyst Consensus Forecast|Consensus Target Erasca Corp (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast ymabs.com (YMAB)|Price Target Chart Aura Bio AURA|CADL: Broker Consensus Forecast|Accuray, Inc. - Analyst Consensus Forecast|Average Forecast Price SELLAS Life Sciences Group|ACTU: Analyst Consensus Forecast|Average Forecast Price citiusonc.com (CTOR)|Price Target Chart tuhurabio.com|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics Corp)|WHWK (Aadi Bioscience) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics)|CSBR - Consensus Target|XBIT: Consensus Target|Fair Value Consensus CVM (cel-sci.com)|OS Therapies Inc (OSTX) - Price Target Chart|Radiopharm Theranostics - Fair Value Consensus|ANL (Adlai Nortye Limited) - Analyst Consensus Forecast|Average Forecast Price Veru VERU|Consensus Target TPST (Tempest Therapeutics)|Analyst Median Target Xilio Therapeutics Inc|Analyst Consensus Forecast RENB (Renovaro)|Analyst Consensus Forecast Mural Oncology plc MURA|Kairos Pharma Limited - Analyst Consensus Forecast|OKUR - Analyst Consensus Forecast|w2.cytomed.sg (GDTC) - Price Target Chart|CRIS - Analyst Median Target|Price Target Chart Apollomics, Inc.|Tharimmune Corporation (THAR) - Analyst Median Target|Analyst Consensus Forecast ADVB|GNPX - Average Forecast Price|Calidi Biotherapeutics - Consensus Target|SBFM: Broker Consensus Forecast|XBIO: Consensus Target|Analyst Median Target Salarius Pharmaceuticals SLRX|PPBT: Analyst Consensus Forecast|AON - Fair Value Consensus|Consensus Target BGNE|CKPT (Checkpoint Therapeutics, Inc) - Analyst Forecast Prices|Price Target Chart Elevation Oncology Inc. (ELEV)|Consensus Target iCAD ICAD|Price Target Chart Ikena Oncology IKNA|Analyst Median Target Notable Labs (NTBL)|Viracta Therapeutics - Analyst Consensus Forecast|Average Forecast Price MorphoSys Inc|NAYA: Analyst Consensus Forecast|Ascentage (AAPGV) - Analyst Consensus Forecast